HOSPITAL-acquired pneumonia remains a lethal ICU threat, but its diagnosis and management are entering a more precise era.
Hospital-Acquired Pneumonia Still Carries a Heavy Burden
Hospital-acquired pneumonia remains the most frequent and deadly hospital acquired infection, with major consequences for intensive care unit mortality, length of stay, and healthcare resource use. This review argues that, despite decades of clinical attention, hospital-acquired pneumonia continues to challenge clinicians because its biology, diagnosis, and progression are more dynamic than earlier models suggested.
Ventilator-associated pneumonia has historically served as the defining form of hospital-acquired pneumonia. Earlier management strategies were shaped by timelines, culture-based diagnostics, and the recognition that the endotracheal tube could be both lifesaving and pathogenic. That framework drove rigid definitions and broad empiric antibiotic use, while also building important knowledge around airway care, aspiration, and biofilm biology.
Hospital-Acquired Pneumonia Definitions Are Evolving
The review describes a major conceptual shift away from the traditional early versus late ventilator-associated pneumonia model. Instead, clinicians are increasingly viewing these infections as part of a continuum of ventilator-associated lower respiratory tract infections, ranging from ventilator-associated tracheobronchitis to ventilator-associated pneumonia.
This perspective places greater emphasis on colonization, biofilm formation, and microbial host interactions as active drivers of infection rather than static background features. The authors also note that recognition of ventilated hospital-acquired pneumonia has further blurred older boundaries, making it harder to rely on conventional categories alone.
Precision Diagnostics May Redefine Future Care
New diagnostic tools are central to this changing landscape. Multiplex polymerase chain reaction and next generation sequencing may allow faster identification of pathogens and resistance patterns, potentially improving both timeliness and precision of treatment. Biomarkers such as procalcitonin may also support antimicrobial stewardship by helping clinicians shorten antibiotic courses when appropriate.
Looking ahead, the review points to a broader transformation in hospital-acquired pneumonia care. Precision diagnostics, immune monitoring, and artificial intelligence may eventually support a more personalized approach that integrates microbial ecology with host response. The key message is clear: better care will likely come not simply from giving antibiotics faster, but from tailoring decisions to the biology of infection and the resilience of the critically ill patient.
Reference
Martin-Loeches I et al. Hospital-acquired pneumonia: Past, present, and perspectives. J Crit Care. 2026;155306. DOI: 10.1016/j.jcrc.2025.155306.
Featured Image: Synthex on Adobe Stock.
